Danaher (NYSE:DHR) Releases FY 2025 Earnings Guidance

Danaher (NYSE:DHR) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 7.800-7.800 for the period, compared to the consensus estimate of 7.710. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a report on Monday, December 29th. Cowen reaffirmed a “buy” rating on shares of Danaher in a report on Wednesday, January 7th. Guggenheim lifted their price target on Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Friday, January 2nd. Redburn Partners set a $220.00 price objective on Danaher in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Twenty-one research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.92.

Danaher Price Performance

Danaher stock opened at $235.40 on Wednesday. The stock has a market cap of $166.27 billion, a price-to-earnings ratio of 48.54, a PEG ratio of 4.25 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The business has a 50-day simple moving average of $226.70 and a 200 day simple moving average of $211.20. Danaher has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the firm posted $1.71 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. On average, research analysts forecast that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s payout ratio is currently 26.39%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 over the last 90 days. 11.20% of the stock is owned by insiders.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Management raised FY‑2025 EPS guidance to $7.80 (vs. consensus ~$7.71), signalling confidence in near‑term earnings execution — a direct driver of upside expectations for the stock.
• Positive Sentiment: Danaher said Q4 revenue is tracking at the high end of guidance on strength in bioprocessing, indicating better-than-expected top-line momentum in a core growth area. Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength — Update
• Positive Sentiment: Equity research support: William Blair reiterated a Buy rating, arguing Danaher’s broad-based outperformance and growth justify a premium multiple — helps underpin investor confidence. Danaher: Buy Rating Reiterated on Broad-Based Outperformance and Premium-Justified Growth Outlook
• Positive Sentiment: Fund flows/manager positioning: Mar Vista flagged Danaher as a top contributor in Q4 for its U.S. Quality strategy, signalling institutional demand from quality-oriented funds. Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
• Neutral Sentiment: Management commentary: Danaher presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail on strategy and outlook but largely reiterative; may not move the stock much unless new incremental news emerged. Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: CEO commentary scheduled/posted around Q4 results (PR release) — offers management color but is expected given the earnings cadence. Danaher CEO to Comment on Financial Performance
• Positive Sentiment: Zacks issued a positive estimate lift for Danaher earnings, adding analyst backing to the outlook. Zacks Research Issues Positive Estimate for Danaher Earnings
• Negative Sentiment: Insider selling flagged in recent reporting — raises near-term caution for some investors and can weigh on sentiment, particularly after a strong run-up. Possible Bearish Signals With Danaher Insiders Disposing Stock
• Negative Sentiment: High valuation (current PE ~48x) and recent gains increase the risk of profit-taking and short-term pullbacks despite positive fundamentals — likely a contributor to today’s weakness.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sivia Capital Partners LLC raised its holdings in Danaher by 6.3% in the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after buying an additional 119 shares during the last quarter. CTC Alternative Strategies Ltd. bought a new stake in shares of Danaher during the second quarter valued at approximately $379,000. CYBER HORNET ETFs LLC raised its holdings in Danaher by 3.6% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 1,750 shares of the conglomerate’s stock worth $347,000 after acquiring an additional 61 shares during the last quarter. Integrated Investment Consultants LLC lifted its position in Danaher by 9.5% in the 3rd quarter. Integrated Investment Consultants LLC now owns 1,722 shares of the conglomerate’s stock valued at $341,000 after acquiring an additional 149 shares in the last quarter. Finally, SIH Partners LLLP bought a new stake in shares of Danaher in the 3rd quarter worth $289,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.